Proteomics International Laboratories Ltd. · ASX:PIQ
Proteomics International Laboratories — Investor Presentation (June 2020)
23 slides from Proteomics International Laboratories's investor presentation, Jun 9, 2020
Slide 1: Investor Presentation: Building a Global Diagnostics Business
Investor Presentation 9th June 2020 BUILDING A GLOBAL ASX: PIQ DIAGNOSTICS BUSINESS
Slide 2: Disclaimer
DISCLAIMER ASX:PIQ This Presentation is provided by Proteomics International Laboratories Ltd (PILL, the Company). You should not rely upon anything in this presentation and/or any information obtained from the Company, its Directors or their associates in deciding whether or not to seek to purchase
Slide 3: Corporate Overview
CORPORATE OVERVIEW ASX:PIQ Proteomics International Laboratories Ltd (ASX: PIQ) is a medical CORPORATE SNAPSHOT – 04/6/2020 technology company at the forefront of predictive diagnostics ASX code PIQ and bioanalytical services Share Price $0.385 Shares on issue (+ ~3m options) 92m PREDICTIVE DIAGNOST
Slide 4: Building a Global Diagnostics Business
BUILDING A GLOBAL DIAGNOSTICS BUSINESS ASX:PIQ PromarkerD, a predictive test for diabetic kidney disease (DKD) is being rolled out now. 463m ENORMOUS MARKET adults have diabetes globally – 1 in 3 currently have DKD. DE-RISKED CLINICALLY PromarkerD clinical studies completed and validated by peer rev
Slide 5: Promarker – Platform Technology
PROMARKER – PLATFORM TECHNOLOGY ASX:PIQ PromarkerTM is a platform technology that can identify unique protein biomarkers ‘fingerprints’ The platform identifies and links the unique protein biomarkers to specific diseases, enabling Proteomics to formulate commercial diagnostic tests 5
Slide 6: PromarkerD Platform & Analytical Services
PromarkerD PLATFORM & ANALYTICAL SERVICES ASX:PIQ PromarkerD – DIABETIC KIDNEY DISEASE TEST ANALYTICAL SERVICES PromarkerD assay can be readily ported to different State-of-the-art biomarker analysis facility platforms Immunoassay Kit Automated Immunoassay LDT ▪ World leading facility in Western Aus
Slide 7: PromarkerD
PromarkerD ASX:PIQ PREDICTIVE TEST FOR DIABETIC KIDNEY DISEASE 7
Slide 8: Market Size?
50% UNDIAGNOSED Nth America & Caribbean ASX:PIQ MARKET SIZE? Europe South & Central America South-East Asia ➢ Hundreds of millions of Middle East & North Africa people could benefit Western Pacific from the PromarkerD test Africa via early treatment to Sth/Ctrl America mitigate the onset of kidney d
Slide 9: A Major Opportunity
A MAJOR OPPORTUNITY ASX:PIQ THE PROBLEM 463 million people have diabetes 1 in 3 diabetic adults currently have chronic kidney disease There are no early symptoms of diabetic kidney disease. Kidney function can fall below 15-20% with no symptoms. There is currently no available mass-market, affordabl
Slide 10: Major Cost/Benefit Factor to Drive Uptake
MAJOR COST/BENEFIT FACTOR TO DRIVE UPTAKE ASX:PIQ With PromarkerD Without PromarkerD Unequivocal Cost Benefit Test Price US$55 Dialysis cost US$72,000 per year Predicts kidney disease with 86% VS ongoing for the patient’s life accuracy up to four years out Unequivocal Patient Benefit Non invasive bl
Slide 11: Janssen Collaboration
JANSSEN COLLABORATION ASX:PIQ Proteomics and Janssen are studying the performance of PromarkerD in predicting decline in kidney function and treatment response in patients from a Janssen completed clinical trial STAGE 1 STUDY COLLABORATION EXPANDED TO STAGE 2 ▪ To assess PromarkerD predictive DKD ca
Slide 12: Janssen Collaboration
JANSSEN COLLABORATION ASX:PIQ CANAGLIFLOZIN (INVOKANA™) COMMERCIAL UPSIDE ▪ Canagliflozin has been sold as a diabetes treatment, ▪ PromarkerD could become a powerful tool for for blood glucose control since 2013 pharmaceutical companies that are: ▪ In 2019 Janssen’s Phase 3 ‘CREDENCE’ clinical trial
Slide 13: Route to Market
ROUTE TO MARKET ASX:PIQ LABORATORY DEVELOPED TEST (LDT) IN VITRO DIAGNOSTIC TEST (IVD) ▪ Immunoassay or Mass spectrometry ▪ Immunoassay kit or automated machine platform ▪ Tests run via certified laboratories - both platforms standard to pathology laboratories ▪ The LDT permits fast ▪ Assay validate
Slide 14: Market Opportunity – PromarkerD
MARKET OPPORTUNITY – PromarkerD ASX:PIQ MARKET SIZE 1 REGION PARTNER (DIABETICS) Spain Patia Europe 3.6m Mexico Patia Biopharma 13m Dominican Republic Omics Global 1.1m TARGET MARKETS United States In Discussions 30m European Union In Discussions 58m Japan In Discussions 10m Total 98m 1. Internation
Slide 15: Diagnostics Pipeline
FURTHER GLOBAL POTENTIAL IN NEW MARKETS Proteomics endeavours to leverage its PromarkerTM Platform to develop and commercialise a suite of diagnostic tests DIAGNOSTICS Potential for faster market adoption for a new diagnostic test, PIPELINE post a successful PromarkerD commercialisation Enormous mar
Slide 16: Endometriosis
ENDOMETRIOSIS ASX:PIQ WHAT IS ENDOMETRIOSIS? A debilitating condition in which tissue that normally lines the uterus grows outside the uterus (on the ovaries, fallopian tubes or the intestines) The most common symptoms are chronic pain and menstrual irregularities Affects 1 in 9 women and costs Aust
Slide 17: COVID-19 Diagnostics & Oxidative Stress
COVID-19 DIAGNOSTICS & OXIDATIVE STRESS COVID-19 DIAGNOSTICS OXIDATIVE STRESS (2-TAG) ▪ Develop a rapid diagnostic test for the identification ▪ The patented technology called "2-tag" measures of the SARS-CoV-2 virus the oxidative stress in a system (i.e. body of human or animal) ▪ Half of people te
Slide 18: Analytical Services
ANALYTICAL SERVICES ASX:PIQ WORLD’S FIRST COMPANY TO RECEIVE ISO 17025 LABORATORY ACCREDITATION FOR PROTEOMICS SERVICES (PROTEIN TESTING) BIOSIMILARS & BIOLOGICS PHARMACOKINETIC TESTING Assisting pharmaceutical companies Pre-clinical and clinical quantitative develop generic drugs testing of any new
Slide 19: Milestones & Upcoming Catalysts
MILESTONES & UPCOMING CATALYSTS EXCEPTIONAL GLOBAL OPPORTUNITY SHARE PRICE CATALYSTS 2020-21 PromarkerD ✓ Proven diagnostics business with global potential ➢ Results from Janssen studies – Stage 1 & 2 ✓ Scalable licensing model with high margins and negligible rollout cost - diagnostic capability to
Slide 20: Appendices - Peer Comparison
APPENDICES - PEER COMPARISON Addressable Market Share FY19 FY19 Net Stock Code Company Focus Market(s) Capitalisation Price Revenue Profit/Loss US$Bn DKD test based on AI and a combination of predictive blood-based biomarkers, £248m £6.9m RENX.LSE genetic factors and electronic health 417p N/A US$9.
Slide 21: Proteomics Vs Typical Biotechs
PROTEOMICS Vs TYPICAL BIOTECHS ALL THE UPSIDE WITHOUT THE CLINICAL RISKS, COSTS & EXTENDED TIMELINES Features PIQ Typical Biotechs Enormous markets ✓ ✓ Minimal clinical risk ✓ X No waiting for results ✓ X Short clinical development (for new products) ✓ X No binary outcome ✓ X Licensing deals execute
Slide 22: Board & Management
BOARD & Terry Sweet FAICD, Chairman Director of several listed companies over the past 30 years in both executive and MANAGEMENT non-executive capacities. Companies include XRFAfrica Scientific Ltd, where Managing Director for 4 years, Western Biotechnology Ltd, Heartlink ASX:PIQ South & he was Ltd,
Slide 23: Contact
CONTACT ASX:PIQ Richard Lipscombe Dirk van Dissel Managing Director Corporate Advisor & Investor Relations T: +61 8 9389 1992 Candour Advisory E: r.lipscombe@proteomicsinternational.com T: +61 408 326 367 www.proteomicsinternational.com E: dirk@candouradvisory.com.au ASX:PIQ
Proteomics International Laboratories — Investor Presentation (June 2020) on 6ix